NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Rosen Law Firm reminds purchasers of Alcobra Ltd. common stock (Nasdaq:ADHD) during the period from March 28, 2014 through November 14, 2014, of the important January 19, 2015 deadline in the class action.
To join the Alcobra class action, go to the website http://www.rosenlegal.com/cases-448.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.
The lawsuit asserts Alcobra misrepresented the results of its Phase 3 clinical trials for its product candidate MDX intended for treating attention deficit hyperactivity disorder. Specifically, the complaint alleges that Alcobra misled investors by misrepresenting or concealing that: (1) MDX did not show a statistically significant benefit over placebo except after it removed certain patients from the Phase 3 study analysis; (2) Alcobra presented its analyses inconsistently, including post hoc analyses outside the original protocols; and (3), as a result Alcobra's statements about the clinical success of MDX, were false and misleading and or lacked a reasonable basis.
The complaint alleges that as a result of Alcobra's misleading statements, its share price has declined, damaging investors.
If you wish to join the class action at no cost go to http://www.rosenlegal.com/cases-448.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.